These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30831572)

  • 1. Association between Trimetazidine and Parkinsonism: A Population-Based Study.
    Kwon J; Yu YM; Kim S; Jeong KH; Lee E
    Neuroepidemiology; 2019; 52(3-4):220-226. PubMed ID: 30831572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study.
    Kim S; Yu YM; Kwon J; Jeong KH; Lee JS; Lee E
    Int J Environ Res Public Health; 2020 Oct; 17(19):. PubMed ID: 33020406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible Parkinsonism linked to trimetazidine.
    Prescrire Int; 2005 Apr; 14(76):63. PubMed ID: 15875344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases.
    Masmoudi K; Masson H; Gras V; Andréjak M
    Fundam Clin Pharmacol; 2012 Apr; 26(2):198-203. PubMed ID: 22044594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries.
    von Bredow D; Toussi M; Samad A; Kaplan S; Domahidy M; de Voogd H; Böhmert S; Ramos RS; Arora D
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1385-1392. PubMed ID: 30379361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice.
    Glezer MG; Vygodin VA;
    Adv Ther; 2018 Sep; 35(9):1368-1377. PubMed ID: 30105656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study.
    Chazov EI; Lepakchin VK; Zharova EA; Fitilev SB; Levin AM; Rumiantzeva EG; Fitileva TB
    Am J Ther; 2005; 12(1):35-42. PubMed ID: 15662290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetazidine: a new cause for drug-induced parkinsonism?
    Sommet A; Azaïs-Vuillemin C; Bagheri H; Rascol O; Montastruc JL
    Mov Disord; 2005 Aug; 20(8):1080-1. PubMed ID: 16007626
    [No Abstract]   [Full Text] [Related]  

  • 9. A drug utilization study to evaluate effectiveness of risk minimization measures for trimetazidine in France, Hungary, Romania and Spain.
    Ehlken B; Toussi M; Samad A; Kaplan S; Domahidy M; de Voogd H; Böhmert S; Silveira Ramos R; Arora D
    J Clin Pharm Ther; 2019 Jun; 44(3):400-408. PubMed ID: 30659627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study.
    Glezer M;
    Adv Ther; 2018 Jul; 35(7):1103-1113. PubMed ID: 29766461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials.
    Marzilli M; Klein WW
    Coron Artery Dis; 2003 Apr; 14(2):171-9. PubMed ID: 12655281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trimetazidine-a new aetiology for extrapyramidal disorders: A case of parkinsonism and akathisia].
    Masmoudi K; Gras-Champel V; Douadi Y; Masson H; Andréjak M
    Therapie; 2005; 60(6):603-5. PubMed ID: 16555505
    [No Abstract]   [Full Text] [Related]  

  • 13. Trimetazidine-Induced Parkinsonism: A Systematic Review.
    Dy AMB; Limjoco LLG; Jamora RDG
    Front Neurol; 2020; 11():44. PubMed ID: 32158422
    [No Abstract]   [Full Text] [Related]  

  • 14. Compound danshen dripping pills combined with trimetazidine in treating unstable angina pectoris: Protocol for a systematic review of randomized controlled trials.
    Yao D; Wang C; Han L; Zhang P; Liu J; Wang B; Zhang E
    Medicine (Baltimore); 2019 Dec; 98(49):e18238. PubMed ID: 31804349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible Parkinsonism linked to trimetazidine (continued).
    Prescrire Int; 2006 Aug; 15(84):136. PubMed ID: 16989026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study.
    Vitale C; Spoletini I; Malorni W; Perrone-Filardi P; Volterrani M; Rosano GM
    Int J Cardiol; 2013 Sep; 168(2):1078-81. PubMed ID: 23200272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Evidence for the Antianginal Efficacy of Trimetazidine from the Russian Observational CHOICE-2 Study.
    Glezer M;
    Adv Ther; 2017 Apr; 34(4):915-924. PubMed ID: 28220388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea.
    Park HY; Park JW; Sohn HS; Kwon JW
    Drug Saf; 2017 Nov; 40(11):1109-1118. PubMed ID: 28634824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent.
    McCarthy CP; Mullins KV; Kerins DM
    Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):266-72. PubMed ID: 27533944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease.
    Jeong S; Cho H; Kim YJ; Ma HI; Jang S
    PLoS One; 2021; 16(3):e0247354. PubMed ID: 33647030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.